News

Update from AML human trial in MiamiMay 4, 2022

Who is entitled to enroll in the trial:
AML /Hi-Risk MDS patients with:

8 weeks of life expectancy.
clinically deteriorating.
have no more available treatments.

In cohort 1 (dose=6mg/m^2) three patients were enrolled.

The first patient was alive with this dose for 5 months.
The second patient was alive with this dose for 1.5 months.
The third

04 May|

Georgetown University at Washington DC has signed a contract with ISK to run a clinical trial with patients with mtKRAS tumorsFebruary 17, 2022

The prestigious medical center Georgetown University at Washington DC has sign a contract with ISK to run a clinical trial with patients with mtKRAS pancreas and colon cancers.

17 Feb|

PHASE 1B/2A Clinical trial startedApril 13, 2021

The Nerofe Phase 1B/2A trial with high risk MDS and AML patients is taking place at the University of Miami Sylvester Comprehensive Cancer Center.

13 Apr|

ISK received the FDA’s approval to start Phase 1b/2a with AML patientsJanuary 9, 2020

09 Jan|

Cooperation with Harvard Medical School (MGH)October 27, 2019

ISK has signed an agreement for cooperation with Harvard Medical School for drug development to treat neurodegenerative diseases

27 Oct|